Protein phosphatase 2A-activating agents
Tocopheryl succinate derivatives according to formula I: are described. These compounds increase the activity of protein phosphatase 2A, can be included in pharmaceutical compositions, and can be used for the treatment of androgen receptor-dependent cancers such as prostate cancer.
1. A compound according to formula I:
wherein R 1 is independently selected from hydrogen and methyl; R 2 is selected from the group consisting of 4,8-dimethyl-non-1-enyl, non-1-enyl, and nonanyl groups; X is a carboxyl, moiety, and n is an integer from 1 to 6, or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein R 2 is a 4,8-dimethyl-non-1-enyl group.
3. The compound of claim 2 , wherein X is a carboxyl moiety.
4. The compound of claim 1 , wherein R 2 is a non-1-enyl group.
5. The compound of claim 4 , wherein X is a carboxyl moiety.
6. The compound of claim 1 , wherein R 2 is a nonanyl group.
7. The compound of claim 6 , wherein X is a carboxyl moiety.
8. A method of treating the development of androgen receptor-dependent cancer in a subject, comprising administering a therapeutically effective amount of a composition including a compound of Formula I:
wherein R 1 is independently selected from hydrogen and methyl; R 2 is selected from the group consisting of 4,8-dimethyl-non-1-enyl, non-1-enyl, and nonanyl groups; X is a carboxyl, moiety, and n is an integer from 1 to 6, or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein the androgen receptor-dependent cancer is prostate cancer.
10. A method of increasing protein phosphatase 2 A (PP 2 A) activity, comprising administering an effective amount of a composition including a compound of Formula I:
wherein R 1 is independently selected from hydrogen and methyl; R 2 is selected from the group consisting of 4,8-dimethyl-non-1-enyl, non-1-enyl, and nonanyl groups; X is a carboxyl moiety, and n is an integer from 1 to 6, or a pharmaceutically acceptable salt thereof.